Sanofi-Aventis (SNY) unit Genzyme will present results of phase II trials of its alemtuzumab multiple sclerosis treatment at an American Academy of Neurology meeting in Hawaii April 9 through April 16.

MAIN FACTS:

- The company will present additional Phase 2 trial safety and efficacy data on the clinically-active disease status of patients through five-years of patient follow-up as well as data describing a measure of vision improvement at the meeting.

-"We look forward to the availability of Phase 3 results in the middle of this

year," said Michael Panzara, Genzyme Group Vice President and Therapeutic Area Head for Multiple Sclerosis and Immune Diseases.

- Genzyme is currently conducting two pivotal Phase 3 trials to evaluate alemtuzumab in the treatment of MS.

- By Paris Bureau, Dow Jones Newswires; +331-4017-1740; mimosa.spencer@dowjones.com
Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Genzyme Charts.
Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Genzyme Charts.